To review all studies reporting the occurrence of white dot syndromes (WDSs) following SARS-COV-2 infection.
Methods
On May 12, 2023, we registered our protocol on PROSPERO [registration number: CRD42023426012]. Five different databases including PubMed, Scopus, Web of Science, Google Scholar, and Science Direct were searched up to May 2023. We included all studies that reported the symptoms of WDSs following SARS-COV-2 infection. The data was extracted using a uniform Excel extraction sheet. All statistical tests were conducted with a 95% confidence interval and a 5% error margin. A p-value of less than 0.05 was considered statistically significant. The publication bias of included studies was assessed using JBI Critical Appraisal Checklist for Case Reports and IHE Quality Appraisal Checklist for Case Series studies.
Results
This review included thirty-two studies involving forty-eight patients. Acute macular neuroretinopathy was the most common disease (70.8%) followed by multiple evanescent white dot syndrome (14.6%) with 58.3% of WDS after their first SARS-COV-2 infection, and paracentral acute middle maculopathy (4.1%). They were mostly unilateral (56.2%). The presenting symptoms were blurred vision (70.8%), visual field disturbance (68.7%), and photopsia (20.8%). About 35.4% of the patients improved by their treatment and future complications were persistent scotoma (4.2%) and macular edema (2.1%).
Conclusion
White dot syndromes are very rare entities. Our findings suggest a possible association between white dot syndrome onset and SARS-COV-2 infection. We recommend ophthalmologists should be aware of this suggested association to deliver better management and patients’ care.
CrawfordCMIgboeliO. A review of the inflammatory chorioretinopathies: the white dot syndromes. ISRN Inflamm2013; 2013: 783190.
2.
QuillenDA, et al.The white dot syndromes. Am J Ophthalmol2004; 137(3): 538–550.
3.
Abu-YaghiNE, et al.White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm2011; 19(6): 426–430.
4.
NguyenMH, et al.Microstructural abnormalities in MEWDS demonstrated by ultrahigh resolution optical coherence tomography. Retina2007; 27(4): 414–418.
5.
LavigneLC, et al.Transient spectral domain optical coherence tomography findings in classic MEWDS: a case report. Arq Bras Oftalmol2014; 77(3): 185–187.
6.
KnickelbeinJESenHN. Multimodal Imaging of the White Dot Syndromes and Related Diseases. J Clin Exp Ophthalmol2016; 7(3).
7.
WangJC, et al.Distinguishing white dot syndromes with patterns of choroidal hypoperfusion on optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retina2017; 48(8): 638–646.
8.
PalejwalaNV, et al.The value of diagnostic work-up in the evaluation of white dot syndromes. Ophthalmic Surg Lasers Imaging Retina2017; 48(7): 540–545.
9.
BeckerMDRosenbaumJT. Essential laboratory tests in uveitis. Dev Ophthalmol1999; 31: 92–108.
10.
LeeCS, et al.Patterns of laboratory testing utilization among uveitis specialists. Am J Ophthalmol2016; 170: 161–167.
11.
JabsDA. Immunosuppression for the Uveitides. Ophthalmology2018; 125(2): 193–202.
12.
KimJE. Intravitreal triamcinolone acetonide for treatment of cystoid macular edema associated with retinitis pigmentosa. Retina2006; 26(9): 1094–1096.
13.
LevinsonRDGonzalesCR. Birdshot retinochoroidopathy: immunopathogenesis, evaluation, and treatment. Ophthalmol Clin North Am2002; 15(3): 343–50, vii.
14.
AkpekEK, et al.Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology2002; 109(8): 1506–1513.
15.
BoselloF, et al.Multiple evanescent white dot syndrome: clinical course and factors influencing visual acuity recovery. Br J Ophthalmol2022; 106(1): 121–127.
16.
ShanthaJG, et al.Choroidal neovascularization associated with birdshot chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina2016; 47(5): 450–457.
17.
SpaideRF, et al.Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina2002; 22(5): 545–549.
18.
RouvasA, et al.Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina2011; 31(5): 871–879.
19.
HawYLYuTCYangCS. A CARE-compliant article: a case report of possible association between recurrence of multiple evanescent white dot syndrome and the Herpesviridae family. Medicine (Baltimore)2020; 99(15): e19794.
20.
MohanN, et al.Polymerase chain reaction evaluation of infectious multifocal serpiginoid choroiditis. Ocul Immunol Inflamm2014; 22(5): 384–390.
21.
WongMCampos-BaniakMGColleauxK. Acute idiopathic blind spot enlargement syndrome following measles, mumps and rubella vaccination. Can J Ophthalmol2019; 54(4): e199–e203.
22.
SenM, et al.COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol2021; 69(3): 488–509.
23.
SerhanHA, et al.SARS-CoV-2 vaccination associated ophthalmic adverse effects. Asia Pac J Ophthalmol (Phila)2022; 11(6): 566–567.
24.
NasiriN, et al.Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res2021; 16(1): 103–112.
25.
ZhouY, et al.Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients. Ophthalmology2020; 127(7): 982–983.
26.
CostaÍF, et al.Ocular findings among patients surviving COVID-19. Sci Rep2021; 11(1): 11085.
27.
CapuanoV, et al.Acute macular neuroretinopathy as the first stage of SARS-CoV-2 infection. Eur J Ophthalmol2023; 33: Np105–Np111.
28.
BellurS, et al.Bilateral acute macular neuroretinopathy after COVID-19 vaccination and infection. Ocul Immunol Inflamm2023; 31(6): 1222–1225.
29.
TomESMcKayKMSarafSS. Bilateral ampiginous choroiditis following presumed SARS-CoV-2 infection. Case Rep Ophthalmol Med2021; 2021: 1646364.
30.
DinhRH, et al.Acute macular neuroretinopathy and coronavirus disease 2019. Ophthalmol Retina2023; 7(2): 198–200.
31.
MukaT, et al.A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol2020; 35(1): 49–60.
32.
PageMJ, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
33.
(IHE), I.o.H.E.Quality Appraisal of Case Series Studies Checklist. 2014.
34.
MoolaSMunnZTufanaruC, et al.Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs Institute Reviewer's Manual2017. Available from: https://reviewersmanual.joannabriggs.org/.
Adzic ZecevicA, et al.Multiple evanescent white dot syndrome associated with coronavirus infection: a case report. Iran J Med Sci2023; 48(1): 98–101.
37.
AidarMN, et al.Low visual acuity due to acute macular neuroretinopathy associated with COVID-19: a case report. Am J Case Rep2021; 22: e931169.
38.
ConradyCD, et al.Coronavirus-19-Associated retinopathy. Ocul Immunol Inflamm2021; 29(4): 675–676.
39.
DavidJAFivgasGD. Acute macular neuroretinopathy associated with COVID-19 infection. Am J Ophthalmol Case Rep2021; 24: 101232.
40.
D'SouzaHSTailorPDOlsenTW. Seeing blue dots after COVID-19 infection. JAMA Ophthalmol2023; 141: 97–98.
41.
De SalvoG, et al.An uncommon cold of the retina. Surv Ophthalmol2022; 67(5): 1553–1558.
42.
El MatriK, et al.Acute macular outer retinopathy as a presumed manifestation of COVID-19. J Fr Ophtalmol2021; 44(8): 1274–1277.
43.
FischerNAWannRCCrossonJN. Acute posterior multifocal placoid pigment epitheliopathy following COVID-19 infection. Am J Ophthalmol Case Rep2023; 29: 101790.
44.
GalloB, et al.Multiple evanescent white dot syndrome and choroidal neovascularization following SARS-COV-2 infection in a patient on dabrafenib and trametinib. Ocul Immunol Inflamm2023; 31(3): 641–648.
GasconP, et al.COVID-19-Associated retinopathy: a case report. Ocul Immunol Inflamm2020; 28(8): 1293–1297.
47.
HawleyLHanLS. Acute macular neuroretinopathy following COVID-19 infection. N Z Med J2022; 135(1563): 105–107.
48.
JainAShilpaINBiswasJ. Multiple evanescent white dot syndrome following SARS-CoV-2 infection - A case report. Indian J Ophthalmol2022; 70(4): 1418–1420.
49.
KarakostaC, et al.Acute macular neuroretinopathy associated with COVID-19 infection: is double heterozygous methylenetetrahydrofolate reductase (MTHFR) mutation an underlying risk factor?Cureus2023; 15(2): e34873.
NicolaiM, et al.Punctate inner choroidopathy reactivation following COVID-19: a case report. Eur J Ophthalmol2022; 32(4): Np6–Np10.
52.
MasjediMPouraziziMHosseiniNS. Acute macular neuroretinopathy as a manifestation of coronavirus disease 2019: a case report. Clin Case Rep2021; 9(10): e04976.
53.
Olguín-ManríquezF, et al.Unilateral acute posterior multifocal placoid pigment epitheliopathy in a convalescent COVID-19 patient. Int J Retina Vitreous2021; 7(1): 41.
54.
Ortiz-SellerA, et al.Ophthalmic and neuro-ophthalmic manifestations of coronavirus disease 2019 (COVID-19). Ocul Immunol Inflamm2020; 28(8): 1285–1289.
55.
PretiRC, et al.Acute macular neuroretinopathy as the presenting manifestation of COVID-19 infection. Retin Cases Brief Rep2022; 16(1): 12–15.
ProvidênciaJ, et al.Serpiginous choroiditis presenting after SARS-CoV-2 infection: a new immunological trigger?Eur J Ophthalmol2022; 32(1): Np97–Np101.
58.
SmellerLToth-MolnarESoharN. White dot syndrome report in a SARS-CoV-2 patient. Case Rep Ophthalmol2022; 13(3): 744–750.
59.
IovinoC, et al.Coincident PAMM and AMN and insights into a common pathophysiology. Am J Ophthalmol2022; 236: 136–146.
60.
ZamaniG, et al.Acute macular neuroretinopathy in a patient with acute myeloid leukemia and deceased by COVID-19: a case report. J Ophthalmic Inflamm Infect2021; 10(1): 39.
61.
Jack KomroJDBWarrenCC. Acute macular neuroretinopathy as a manifestation of COVID-19. Ophthalmology Case Reports2021; 5(1): e265–e268.
62.
JalinkMBBronkhorstIHG. A sudden rise of patients with acute macular neuroretinopathy during the COVID-19 pandemic. Case Rep Ophthalmol2022; 13(1): 96–103.
63.
VirgoJMohamedM. Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye (Lond)2020; 34(12): 2352–2353.
64.
Yılmaz ÇebiAKılıçarslanOUçarD. Coincident acute macular neuroretinopathy and paracentral acute middle maculopathy in COVID-19. Turk J Ophthalmol2023; 53(2): 120–123.
65.
BollettaE, et al.Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J Clin Med2021; 10(24): 5960.
66.
RousseauAFenollandJRLabetoulleM. SARS-CoV-2, COVID-19 and the eye: an update on published data. J Fr Ophtalmol2020; 43(7): 642–652.
67.
FawziAA, et al.Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging. Retina2012; 32(8): 1500–1513.
68.
ØstergaardL. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep2021; 9(3): e14726.
69.
TavallaliAYannuzziLA. MEWDS, common cold of the retina. J Ophthalmic Vis Res2017; 12(2): 132–134.
70.
ChoudharyMMHajj-AliRALowderCY. Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol2014; 2014: 403042.
71.
SinghRP, et al.Th17 cells in inflammation and autoimmunity. Autoimmun Rev2014; 13(12): 1174–1181.
72.
XuB, et al.Transient increase in patient numbers with “acute macular neuroretinopathy” post SARS-CoV-2 infection-case series during the first surge of infection in December 2022. J Inflamm Res2023; 16: 2763–2771.
73.
BhavsarKV, et al.Acute macular neuroretinopathy: a comprehensive review of the literature. Surv Ophthalmol2016; 61(5): 538–565.
74.
FengH, et al.The characteristics of acute macular neuroretinopathy following COVID-19 infection. BMC Ophthalmol2024; 24(1): 19.
75.
HanffTC, et al.Thrombosis in COVID-19. Am J Hematol2020; 95(12): 1578–1589.
76.
GabaWH, et al.Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia. Am J Case Rep2020; 21: e927691.
77.
Abu El-AsrarAMHerbortCPTabbaraKF. Differential diagnosis of retinal vasculitis. Middle East Afr J Ophthalmol2009; 16(4): 202–218.
78.
DemirG, et al.Ischemic stroke in the setting of supratherapeutic international normalized ratio following coronavirus disease 2019 infection: a case report. J Med Case Rep2023; 17(1): 223.
79.
Abu SerhanH, et al.Ocular Vascular Events following COVID-19 Vaccines: A Systematic Review. Vaccines (Basel)2022; 10: 2143.
80.
OrganizationWH. WHO Coronavirus (COVID-19) Dashboard. 2023 [cited 2023 27/08/2023]; Available from: https://covid19.who.int/. 2023.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
